B·DEBATE International Center for Scientific Debate BARCELONA

Sant Joan de Déu HOSPITAL MATERNOINFANTIL - UNIVERSITAT DE BARCELONA

Sant Joan de Déu Research Foundation

EDUARD SABIDÓ

CV

PARTICIPANT AT:

CONNECTING THE GROWING BRAIN

UNDERSTANDING NEUROPAEDIATRIC DISEASES THROUGH SYNAPTIC COMMUNICATION

November, 26th-27th, 2015, Barcelona

Eduard Sabidó, Head of the Proteomics Unit, Centre de Regulació Genòmica and Universitat Pompeu Fabra, Barcelona, Spain

Eduard Sabidó is the head of the CRG/UPF Proteomics Unit at the Centre for Genomic Regulation and University Pompeu Fabra. Eduard Sabidó holds a BS degree in Biochemistry (2003), Biology (2008) and Computer Science (2011), and a PhD in Biology (2009) from Universitat de Barcelona. He has made a postdoctoral stage at the Swiss Federal Institute of Technology (ETH Zürich, 2009-2012) and he did long- and short-term visits at the University of California in Davis and the Scripps Research Institute in San Diego. Dr. Eduard Sabidó has a broad experience in the fields of activity-based proteomics and targeted proteomics.

B·DEBATE IS AN INITIATIVE OF:

biocat "la Caixa" Foundation

B·DEBATE International Center for Scientific Debate BARCELONA

Sant Joan de Déu HOSPITAL MATERNOINFANTIL - UNIVERSITAT DE BARCELONA

Sant Joan de Déu Research Foundation

EDUARD SABIDÓ

ABSTRACT

PARTICIPANT AT:

CONNECTING THE GROWING BRAIN
UNDERSTANDING NEUROPAEDIATRIC DISEASES THROUGH SYNAPTIC COMMUNICATION

November, 26th-27th, 2015, Barcelona

Eduard Sabidó, Head of the Proteomics Unit, Centre de Regulació Genòmica and Universitat Pompeu Fabra, Barcelona, Spain

Metabolomics and Proteomic of the CSF

Mass spectrometry-based proteomics is an analytical technique for the identification and quantification of proteins and in the last few years it has emerged as a powerful analytical technique to discover protein biomarkers for neurological diseases. A particularly interesting application is the use of targeted proteomics assays to stratify patients and predict the prognosis of neural disease such as multiple sclerosis. In this talk we will illustrate how we took advantage of the capabilities of targeted mass spectrometry to establish a diagnostic molecular classifier with high sensitivity and specificity able to differentiate between clinically isolated syndrome patients with a high and a low risk of developing multiple sclerosis.

B·DEBATE IS AN INITIATIVE OF:

biocat "la Caixa" Foundation